Dejan Juric

home / authors / dejan-juric

Articles

18 Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor (ER) Degrader, Plus Palbociclib in ER-Positive/Human Epidermal Growth Factor Receptor 2 (HER2)–Negative Advanced Breast Cancer: Phase 1b Cohort

18 Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor (ER) Degrader, Plus Palbociclib in ER-Positive/Human Epidermal Growth Factor Receptor 2 (HER2)–Negative Advanced Breast Cancer: Phase 1b Cohort

Erika P. Hamilton, MD;Rinath M. Jeselsohn;Sara A. Hurvitz, MD;Dejan Juric;Hyo S Han;Melinda L. Telli, MD;George Zahrah;Rita Nanda, MD;Yuanyuan Zhang;Weiwei Tan;Elizabeth Duperret;Eric Zhi;Cecile Mather;Anne F. Schott, MD
August 10th 2024
9 Phase 1 TROPION-PanTumor01 Study Evaluating Datopotamab Deruxtecan (Dato-DXd) in Unresectable or Metastatic Hormone Receptor–Positive/ Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer

9 Phase 1 TROPION-PanTumor01 Study Evaluating Datopotamab Deruxtecan (Dato-DXd) in Unresectable or Metastatic Hormone Receptor–Positive/ Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer

Aditya Bardia, MD, MPH;Ian E. Krop;Dejan Juric;Takahiro Kogawa;Erika P. Hamilton, MD;Alexander Spira, MD, PhD, FACP;Toru Mukohara;Takuya Tsunoda;Senthil Damodaran;Funda Meric-Bernstam, MD
April 28th 2023
15 Updated Expert Consensus Recommendations for Managing Hyperglycemia and Rash in Patients With PIK3CA-Mutated, Hormone Receptor–Positive (HR+), Human Epidermal Growth Factor Receptor 2–Negative (HER2–) Advanced Breast Cancer Treated With Alpelisib

15 Updated Expert Consensus Recommendations for Managing Hyperglycemia and Rash in Patients With PIK3CA-Mutated, Hormone Receptor–Positive (HR+), Human Epidermal Growth Factor Receptor 2–Negative (HER2–) Advanced Breast Cancer Treated With Alpelisib

Emily J. Gallagher;Heather Moore;Mario E. Lacouture, MD;Susan F. Dent;Azeez Farooki, MD;Marcus D. Goncalves;Claudine Isaacs, MD;Abigail Johnston;Dejan Juric;Zoe Quandt;Laura Spring;Brian Berman;Melanie Decker;Gabriel N. Hortobagyi, MD, FACP;Benjamin H. Kaffenberger;Bernice Y. Kwong;Timothy Pluard;Ruta Rao, MD;Lee Schwartzberg, MD, FACP;Michael S. Broder
April 28th 2023
28 Pooled Analysis of Post- Progression Treatments After Firstline Ribociclib + Endocrine Therapy in Patients With HR+/HER2− Advanced Breast Cancer in the MONALEESA-2, -3, and -7 Studies

28 Pooled Analysis of Post- Progression Treatments After Firstline Ribociclib + Endocrine Therapy in Patients With HR+/HER2− Advanced Breast Cancer in the MONALEESA-2, -3, and -7 Studies

Kevin Kalinsky, MD, MS;Erika P. Hamilton, MD;Laura Spring;Peter A. Fasching;Sandra Franco, MD;Richard De Boer;Javier Cortes;Dejan Juric;Aditya Bardia, MD, MPH;Sina Haftchenary;Agnes Lteif;Juan Pablo Zarate;Liyi Cen;Patrick Neven, MD, PhD
April 27th 2023

Latest Updated Articles

NSABP B-42 trial results show that the assay was predictive of extended letrozole therapy response, identifying a patient subset with improved outcomes.
Published: August 9th 2024 | Updated: August 14th 2024
Gene Assay May Predict Extended Letrozole Benefits in Breast Cancer Subsets
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Published: June 2nd 2024 | Updated: June 3rd 2024
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Data from the CheckMate-67T trial support the biologics license application for subcutaneous nivolumab in multiple solid tumors.
Published: May 6th 2024 | Updated: May 21st 2024
FDA Accepts BLA for Subcutaneous Nivolumab in Solid Tumor Indications
A 71-Year-Old Male Presents for Evaluation of Painless Bump on His Chin
Published: May 27th 2011 | Updated: November 21st 2024
A 71-Year-Old Male Presents for Evaluation of Painless Bump on His Chin
Patient With Supraglottic Squamous Cell Carcinoma Develops Painful Swelling on Both Great Toes
Published: August 26th 2011 | Updated: November 21st 2024
Patient With Supraglottic Squamous Cell Carcinoma Develops Painful Swelling on Both Great Toes
How to Radiologically Assess and Follow Response After Treatment of Hepatocellular Carcinoma
Published: April 21st 2021 | Updated: November 21st 2024
How to Radiologically Assess and Follow Response After Treatment of Hepatocellular Carcinoma